Skip to main content

MBL-Deficient

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Prothya Biosolutions
Prothya BiosolutionsBelgium - Brussels
1 program
1
Mannan Binding LectinPhase 21 trial
Active Trials
NCT00138736Completed12Est. Oct 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prothya BiosolutionsMannan Binding Lectin

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

NCT00138736Prothya BiosolutionsMannan Binding Lectin

Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia

Start: Apr 2004Est. completion: Oct 200612 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.